Aktienanalyse zu Nkarta Inc (NKTX)NKTXNkarta Inc

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nkarta Inc is currently trading at $1.52, significantly below its 52-week high of $3.72, indicating potential upside. However, the stock has a very low RSI of 14.286, suggesting it is oversold, but also reflects ongoing financial struggles with a net loss of $40.37 million in Q2 2026. The upcoming earnings report on November 9, 2026, is crucial, with an estimated EPS of -0.40, which may further impact investor sentiment.